tiprankstipranks
Carisma Therapeutics Grants Executive Stock Options for Retention
PremiumCompany AnnouncementsCarisma Therapeutics Grants Executive Stock Options for Retention
1M ago
Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525
PremiumThe Fly
Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525
2M ago
Carisma Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
PremiumThe Fly
Carisma Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
2M ago
Carisma Therapeutics presents data for macrophages in liver fibrosis
PremiumThe FlyCarisma Therapeutics presents data for macrophages in liver fibrosis
2M ago
Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
PremiumThe Fly
Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
3M ago
Carisma Therapeutics initiated with a Buy at BTIG
PremiumThe Fly
Carisma Therapeutics initiated with a Buy at BTIG
3M ago
Carisma Therapeutics nominates first lead candidate in Moderna collaboration
PremiumThe FlyCarisma Therapeutics nominates first lead candidate in Moderna collaboration
7M ago
Carisma Therapeutics: FDA clears IND application for CT-0525
PremiumThe Fly
Carisma Therapeutics: FDA clears IND application for CT-0525
8M ago
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
PremiumPress Releases
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100